

Fasanella  
Modern Advances in Cataract Sur



ncott

# Modern Advances in Cataract Surgery

**EDITOR** R. M. Fasanella, M.D.

*Diplomate, American Board of Ophthalmology; Associate Clinical Professor of Ophthalmology, Yale University School of Medicine; Diplomate, Pan American Congress of Ophthalmology; Fellow, American Academy of Ophthalmology and Otolaryngology; Member, Association for Research in Ophthalmology; Member, New York Society for Clinical Ophthalmology*

**ASSOCIATE EDITOR** Barbara J. Matthews

**DRAWINGS** Robert Bray Wingate, A.B., M.S.



**J. B. LIPPINCOTT COMPANY**

**PHILADELPHIA AND MONTREAL**

COPYRIGHT © 1963, BY J. B. LIPPINCOTT COMPANY

This book is fully protected by copyright and, with the exception of brief extracts for review, no part of it may be reproduced in any form without the written permission of the publishers.

Distributed in Great Britain by  
Pitman Medical Publishing Co., Limited, London

Library of Congress Catalog Card No. 63-12498

Printed in the United States of America

MODERN ADVANCES  
IN CATARACT SURGERY

## CONTRIBUTORS

JOAQUIN BARRAQUER, M.D.

*Director, Instituto Barraquer, Barcelona, Spain*

F. PHINIZY CALHOUN, JR., M.D.

*Professor of Ophthalmology, Chairman of the Department and Director of Montgomery Laboratory of Ocular Pathology (Emory), Atlanta, Georgia*

WOLFGANG HÖPPING, M.D.

*Facharzt für Augenkrankheiten, Essen, Germany*

TADEUSZ KRZAWICZ, M.D.

*Professor of Ophthalmology, Director of Ophthalmological Clinic, Medical Academy, Lublin, Poland*

GERD MEYER-SCHWICKERATH, M.D.

*Professor of Ophthalmology, University of Bonn, Head of the Eye Department, Municipal Eye Clinic, Essen, Germany*

BENEDETTO STRAMPELLI, M.D.

*Chief of Ophthalmology, Reunited Hospitals, Docent in Ophthalmology, Eye Clinics and University of Rome, Italy*

This book is dedicated not to a single individual  
but to all those persons who have made it possible.

It is dedicated to my patients, especially one, A.B.;  
it is dedicated to my teachers, especially E.B.S. and E.M.A.;  
it is dedicated to my staff, especially B.J.M.  
and to my family, especially P.



## Preface

In the last few years certain changes have taken place in surgery of the cataract. Drugs like alpha-chymotrypsin to cause zonulolysis and urea and mannitol in treating cases complicated by glaucoma have proved to be valuable assets in the successful outcome of procedures related to cataract extraction. Nystatin and amphotericin B\* have played an increasingly useful role in cases with fungal disease. New instruments such as the light coagulator and the operating microscope have been designed to facilitate the technic of cataract surgery. New sutures and needles have been introduced which ensure easier and better wound closures. The practice of removing both cataracts in a patient during one hospital admission is not new and is gaining popularity in certain areas of the United States, although generally it is not favored.

Nevertheless, while these new trends have removed some problems formerly presented in cataract surgery, they are not foolproof. Constant re-evaluation is needed to avoid the pitfalls which will be met in all advances. For example, if alpha-chymotrypsin is improperly used, it may lead to complications such as wound separation; likewise, the light coagulator can cause damage to the cornea and the retina if it is handled improperly.

\* Nystatin and amphotericin B as antifungoidal agents in ocular infection.

This book is meant to be practical and is written for the practicing ophthalmic surgeon. Because the literature is so voluminous and because critical evaluation is necessary in view of overzealous statements, an attempt has been made to interpret for the busy practitioner the various authoritative views which are justifiable in the present state of our knowledge. Based on practical experience an attempt also has been made to delineate the various steps that should be taken in cataract surgery. Not all of the old procedures have been abandoned or replaced. There is still room for the employment of such procedures in certain specific conditions. But in almost every case, the material is based on questions that have actually been asked at lectures and meetings. These have been regrouped to fit the sequence of cataract surgery steps. In addition, some problems for which there are no definitive solutions at this time have been included. Also included are articles by Phinizy Calhoun, Joaquin Barraquer, Benedetto Strampelli and Wolfgang Höppling and G. Meyer-Schwickerath. Also introduced is the work of T. Krwawicz, who, by his method of extracting intumescent lenses by the application of low temperature, offers a new approach which may make possible a greater number of intracapsular extractions.

The compiling of this book has been made possible by the work of many people in this field and by those with whom we have exchanged ideas. It is almost

impossible to list all of them but we fully realize that any value that this book may have rests on the fact that we have been associated with these people.

**R. M. FASANELLA**



## Acknowledgments

A surgeon turned writer cannot be objective enough to detect his own faults and, as is customary, must rely on his friends to read his material with a critical eye. I owe a debt of thanks to my busy colleagues who sacrificed their time to review portions of this book. Grateful acknowledgment is hereby made to Dr. H. Saul Sugar for his help with Glaucoma and Cataracts; to Dr. Frederick C. Cordes for his generous assistance with Congenital Cataracts; to Dr. Wilfred Fry who was kind enough to review Corneal Dystrophy and Cataracts; to Dr. Morton Rosenthal for his assistance with Myopia and Detachment; and to Dr. Louis Nahum who was of great help editorially.

I am particularly grateful to Drs. Ramon Castroviejo and Algernon Reese who aided me with many portions of this book and to Drs. Edmund B. Spaeth and Andrew S. Wong for reading every page of the manuscript and for furnishing me with their valuable criticism and counsel.

The following were of great assistance in the preparation of the manuscript: Miss Mary Czuckery, Mr. Anthony Fontana, Mrs. Mary Hibson, Dr. R. Cordero Moreno, Dr. H. Van Den Beld C., Dr. José Barraquer, Dr. Enrique Ariza H., Dr. U. M. Carbajal, Dr. Louis Girard, Dr. W. A. J. VanHeuven and Dr. Jerome Freedman.

I have been fortunate in having the services of the well-known illustrator, Mr. Robert Bray Wingate, A.B., M.S., who has had extensive experience in ophthalmic art at the Ocular Research Unit of Walter Reed General Hospital, Washington, D. C.

Finally, I am indebted to the Storz Instrument Company for providing the instrument plates and to the numerous authors and publishers who granted permission for the use of their materials in this book.

R. M. F.

## Introduction—The Use of Alpha-Chymotrypsin

A milestone in cataract surgery was the report of the Committee on the Use of alpha-Chymotrypsin which was presented at the 64th Annual Session of the American Academy of Ophthalmology and Otolaryngology, October 11-16, 1959, in Chicago. Here a national survey on the facility of cataract extraction and on operative and immediate postoperative complications with the use of the enzyme is best summarized in the introduction and summary by Derrick Vail, M.D., the Chairman of the Committee.\*

We have heard from Dr. Schwartz that this enzyme isolated by Kunitz and Northrop has been available since 1933. It is a protein and thus is capable of producing an allergic reaction in the eye in sensitized individuals. Clinically, however, this seems to be more of a theoretical than a practical consideration, although such a possibility must be borne in mind and cases of allergic reactions following systemic use have been reported. Alpha-chymotrypsin is a proteolytic enzyme, having a specificity of action at certain peptide bonds, but it is capable of hydrolyzing other bonds such as esters, amides, hydroxyamides, hydrazides, and even carbon-carbon bonds. The optimum pH for maximum velocity of hydrolysis of protein and synthetic substrates by alpha-chymotrypsin is usually between 7 and 9.

Certain enhancers and inhibitors of the

enzyme have been discovered. Among the enhancers is calcium chloride, sometimes used in the vehicle for ophthalmic use. It should be borne in mind that while calcium chloride may enhance the effect of the enzyme, it also may prolong its activity. Further investigation of this point must be carried out.

Among the inhibitors are DFP and beta-phenyl-propionic acid. What, if any, practical use will develop from this information is hard to see at this stage of our knowledge.

Dr. von Sallmann helped us very much when he reported that he was unable to produce an allergic reaction in animals experimentally sensitized to this enzyme by installation or by injection subconjunctivally, or in the anterior chamber, or in the vitreous. This evidence supports wide clinical impressions.

His studies on the effect of this substance on the corneal endothelium are of great importance to us. His illustrations show these effects beautifully. However, we are told that the injection of a 0.9 per cent solution of sodium chloride by itself will produce the same type of injury, although to a lesser degree. In other words the addition of alpha-chymotrypsin is a slight increment in potential damage to the endothelial cells. This is important in considering the question of the cause of striate keratitis, which is found more frequently when alpha-chymotrypsin is used than otherwise.

However, when the enzyme reaches into the corneal stroma through extensively damaged endothelium, a heavy opacity results. Such opacities also occur with a 0.9 per cent solution of sodium chloride. The corneal changes are of a transient nature as a rule, and Dr. von Sallmann concludes that it was

\* Vail, Derrick: Report of the Committee on the Use of alpha-Chymotrypsin in Ophthalmology, Summary, *Trans. Am. Acad. Ophthalm. Otolaryng.* 64:54, 1960.

improbable that a specific enzymatic action was the cause of the lesion. Using a different technic, which may or may not be a factor, David Shoch and his co-workers found no evidence of endothelial damage in the eyes of twenty-four rabbits. This discrepancy in the findings needs to be resolved.

Finally, Dr. von Sallmann confirms the histologic findings of the St. Louis workers, Ley, Holmberg and Yamashita, who showed by electromicroscopic studies that the zonule fibers are fragmented by the action of the enzyme.

Dr. Maumenee gives us a horrifying picture of what happens when the retina is placed in a solution containing 150 units of alpha-chymotrypsin. However, this concentration and the duration of exposure exceed, by far, the same factors when alpha-chymotrypsin is employed in cataract surgery.

Maumenee's report shows that the supporting structure of the retina is more sensitive to the enzyme than is the rest of the retinal tissue. This damage occurs when alpha-chymotrypsin is injected into the vitreous of an experimental animal. This may have some clinical importance in suggesting that the enzyme should not be used in cases of fluid vitreous or subluxated lens, or where the hyaloid membrane is not intact.

Dr. Troutman's report involved an enormous amount of analytic work on the questionnaires and is still somewhat incomplete. However, enough facts have been gathered to warrant the following conclusions:

1. The incidence of striate keratitis is greater when the enzyme is employed. We believe that this is due largely to mechanical injury to the endothelium by instruments, either forceps or erisophake (about equal incidence). The marked decrease in the depth of the anterior chamber consequent to the forward dislocation of the lens means much less room for manipulation and a greater chance for rubbing or scraping of the endothelium of the cornea than otherwise. The deleterious action of a solution, either of saline solution or alpha-chymotrypsin, upon the corneal endothelium must be considered a part of this problem. The preparation of the solution and the vehicle used may also play a part. As yet we don't know.

2. A 1:10,000 dilution is as effective as

a 1:5000 dilution. This finding conflicts with the experience of Barraquer and needs further investigation.

3. Great care must be devoted to the preparation of a fresh solution, the technic and instrumentation of its injection into the posterior chamber, and its removal by irrigation of the anterior chamber two minutes after injection.

4. A very high percentage of surgeons "felt" that the facility of extracting the lens was enhanced by use of the enzyme. This clinical impression was beautifully supported by the double blind study conducted by Dr. Schwartz.

5. One of the most important findings of this statistical study is the marked decrease in the number of ruptured capsules that occurred when the enzyme was employed in the operation on one eye, when compared with the incidence of ruptured capsules that occurred in the other eye of the same individuals when the enzyme was not used. In other words, the use of the enzyme means fewer ruptured capsules.

6. While we cannot be sure, because of the difficulty in getting figures in a comparable control series, we believe that the complications that occur during the operation or during the healing postoperative stage are no greater or no less whether the enzyme is used or not. The one and major exception to this statement is the finding that 0.2 per cent of the total cases had posterior luxation of the lens, a most serious complication, although known to occur rarely in cases in which the enzyme was not used. The figures Dr. Troutman has given us regarding the presentation of vitreous and the actual loss of vitreous seem high, and they probably are, but we do not know what the percentages would be in an up-to-date comparable control series. Theoretically, at any rate, we should expect a higher percentage of loss of vitreous when the enzyme is used, considering that we are dealing with a dislocated lens.

7. Is the incidence of absent or shallow chambers greater when the enzyme is used? This was a difficult question to answer. Much depends on the technic of the operation, i.e., type of incision, whether multiple sutures were used, and so on. Our figures do show an increase of such cases, especially in the

lower age group. Reports in the literature on the use of alpha-chymotrypsin indicate that the wound healing is not retarded, and catgut sutures do not dissolve. More facts are needed.

8. Barraquer and others have mentioned the occasional case in which edema of the conjunctival flap has occurred. Our studies give us no information on this point. Barraquer believes that this is due to (a) incision too far in the cornea and (b) lack of proper wound closure.

9. It is possible that the round pupil operation has fewer complications than result from complete iridectomy. More study along this line is needed.

10. This report cannot tell us anything of the late effects of the use of alpha-chymotrypsin; the time is too short. A further report on this series a year or so from now should be made. We know from Dr. Maumenee's experimental studies that the retina can be damaged by the enzyme when it is injected into the vitreous. We don't know whether the pars ciliaris retinae is injured under the conditions of cataract surgery by seepage of the enzyme into Petit's canal. If it is, a higher incidence of aphakic retinal detachment might be expected. If it isn't, a lower incidence might occur, because the mechanical pull of the zonular fibers is abolished during the operation.

11. Modifications of our present technic and new instrumentation devised to assist us

in the removal of the lens in view of the altered conditions because of zonulolysis will undoubtedly occur.

On the basis of the information obtained from this and a partial survey of the growing literature, your Committee recommends that alpha-chymotrypsin should not be used in the surgery of the lens in the following conditions:

1. Cases in which the patient is under twenty years of age.
2. Cases of endothelial dystrophy.
3. Cases of subluxated lenses.
4. Cases of traumatic cataract, especially when vitreous is presented.

Finally, we beg you to remain conservative in your actions regarding the use of zonulolysis until we know much more about it. . . .


With the passage of time, the initial wave of enthusiasm and the hope that this drug might help cataract surgery in all age groups have proved to be overly optimistic, but new vistas in intraocular surgery have been opened up. There are, of course, problems and obstacles ahead, but it has been said that the "impossible takes just a little longer." Fortunately, to explore that small sphere called the eye, there are pioneers such as Ridley, Meyer-Schwickerath and Barraquer.

# Contents

1. PREOPERATIVE CONSIDERATIONS	1
Preoperative Evaluation of Cataract Patients	1
Monocular Cataract	2
Ligamentum Hyaloideo-Capsulare	3
Surgical Treatment	6
Summary	7
Infections	7
Preoperative Cultures and Antibiotics	8
Fungal Infections and Steroids	8
Choice of Operation	8
Tear Passageways	8
Other Prophylactic Considerations	9
Surgery of Binocular Cataracts During One Hospital Admission	9
2. OPERATIVE CONSIDERATIONS	12
Anesthesia	12
General Anesthesia	12
Local Anesthesia	13
Anesthetic Aids for Local Anesthesia	14
Cardiac Arrest: Management	17
Diagnosis	17
Treatment	17
External Cardiac Massage	17
Digital Massage	18
Ocular Hypotensive Agents	18
Lid Retraction	18
Flieringa-Bonaccolto Ring	20
Incisions and Closures	21
Position of Incision When Corneal Dystrophy, Diabetes and Bleeding Tendency Have Been Diagnosed Preoperatively	26
Position of Incision for Cataract Following a Filtering Procedure	26
Hypotensive Measures for Extracting Cataracts in the Presence of Glaucoma	29
Considerations Related to Technic	30

2. OPERATIVE CONSIDERATIONS—( <i>Continued</i> )	
Size of Incision	35
Hemostasis	36
Problems Related to Suture Material	36
Number of Sutures	38
Surgery of the Iris	39
Round Pupils Vs. Full Iridectomies	39
Tendency for Iris Prolapse	55
Iris Pigment Loss With the Use of Alpha-Chymotrypsin	55
Iris Prolapse (Recent)	56
Iris Prolapse (Late)	56
Hammock Pupil	57
3. PROBLEMS RELATED TO THE LENS EXTRACTION	63
Vomiting	63
Extracapsular or Intracapsular Extraction	64
Sliding Vs. Tumbling and Alpha-Chymotrypsin	65
Alpha-Chymotrypsin Irrigating Cannulas	67
Capsule Forceps Vs. Erisophake and Alpha-Chymotrypsin	68
Inability to Grip the Capsule	71
Loss of Grip on the Capsule	72
Rupture of the Capsule During Cataract Extraction	72
Posterior Dislocation of the Lens	76
Hypermature Lens in the Vitreous	76
Lavage of the Anterior Chamber and Alpha-Chymotrypsin	77
Balanced Solutions	77
Air in the Anterior Chamber	77
Vitreous Prolapse	78
Prophylaxis	78
Actual Management of Vitreous Prolapse: Further Generalizations	82
Loss of Formed Vitreous	83
When Not Preserving the Round Pupil	86
If the Round Pupil Is To Be Preserved	88
Discussion	89
Summary	91
Expulsive Choroidal Hemorrhage	91
4. CATARACT EXTRACTION IN SPECIAL CASES	93
Congenital Cataracts	93
Introduction	93
Surgical Classification of Congenital Cataracts	95
Iridectomy for Optical Purposes	96
Extracapsular Extractions (Modifications)	96
Intracapsular Extraction	114
Complications of Congenital Cataracts: Further Comments	115

4. CATARACT EXTRACTION IN SPECIAL CASES—( <i>Continued</i> )	
Summary and Conclusions	117
Traumatic Cataract	117
Intralenticular Foreign Bodies	118
Traumatic Cataract in Children: Prognosis	119
Cataract Surgery in Diabetics	120
Myopia and Detachment	121
Prophylactic Steps	121
Possible Indications and Therapy	121
Optimal Time for Repairing Retinal Detachment Following Cataract Surgery	124
Summary and Conclusions	124
Corneal Dystrophies, Cataracts and the Use of Alpha-Chymotrypsin	125
Management of Dystrophy Prior to Cataract Extraction	126
Cataract Surgery	127
Technic of Cataract Surgery	127
Hereditary Deep Corneal Dystrophy	128
Summary	130
Glaucoma and Cataracts	130
Primary Glaucoma—Open-Angle Type	133
Primary Glaucoma—Angle-Closure Type	133
Secondary Glaucoma	134
Types of Glaucoma Surgery	144
Simultaneous Glaucoma and Cataract Surgery	145
Some General Considerations Related to the Technic of Simultaneous Glaucoma and Cataract Surgery	145
Summary and Conclusions	145
Uveitis and Cataract	146
Cataract Extraction Following Corneal-Graft Surgery	146
Lamellar Transplants and Cataract Surgery	147
Summary and Conclusions	148
5. POSTOPERATIVE COMPLICATIONS	150
Striate Keratitis	150
Corneal Edema and Bullous Keratopathy	150
Differential Diagnosis and Prophylaxis	150
Prophylactic Considerations	151
Early Treatment of Corneal Edema	151
Late Treatment or the Bullous Keratopathy Stage	152
Flat Chamber Following Cataract Extraction	153
Preventive Treatment	153
Conservative Treatment	154
Surgical Treatment	155
Postoperative Hyphema	156
Filtering Cystic Cicatrix	157





5. POSTOPERATIVE COMPLICATIONS—( <i>Continued</i> )	
Treatment of Iris Cysts (True Serous) Following Cataract Extraction	158
Epithelial Ingrowth	160
Clinical and Pathologic Picture	160
Prophylaxis	161
Capsulotomies and Capsulectomies	161
Thin Capsule	161
Medium Capsule	163
Thick Capsule and Cortex	164
Summary	165
Macular Edema and Cysts	166
Postoperative Infections	167
Postoperative Iridocyclitis	168
Normal Trauma Incident to Cataract Surgery	168
Incarceration of Foreign Materials in the Wound	168
Lens-induced Uveitis	168
Summary	169
Fungal Endophthalmitis Following Cataract Extraction	169
Laboratory Diagnosis	169
Treatment	169
Optic Neuritis Following Cataract Surgery	170
Postoperative Considerations of Cataract Patients	171
6. ENZYMATIC ZONULOLYSIS IN LENS EXTRACTION	173
Joaquin Barraquer, M.D.	
7. ANTERIOR <sup>1</sup> CHAMBER LENS	180
Professor Benedetto Strampelli	
8. LIGHT COAGULATION IN THE TREATMENT AND PREVENTION OF COMPLICATIONS AFTER CATARACT SURGERY	185
Gerd Meyer-Schwickerath, M.D., and Wolfgang Höpping, M.D.	
Light Coagulation of Iris Prolapse	185
Technic	185
The Treatment of Updrawn Pupil or Pupillary Membrane	187
Technic	187
Prophylaxis of Aphakic Detachment	189
Summary	190
9. CATARACT EXTRACTION BY APPLICATION OF LOW TEMPERATURE	191
Tadeusz Krwawicz, M.D.	
Introduction	191
Method	192
Enzymatic Zonulolysis	193
Management of Complications	194
Summary	195

10. THE MANAGEMENT OF THE DISLOCATED LENS . . . . . 196

    F. Phinizy Calhoun, Jr., M.D.

    Introduction . . . . . 196

    Indications for Planned Removal of Dislocated Lenses . . . . . 196

        Luxations into the Anterior Chamber . . . . . 197

        Subluxations . . . . . 198

        Luxations into the Vitreous . . . . . 199

    Advantages of the Double-Needle Operation . . . . . 200

    Complications of the Double-Needle Operations . . . . . 200

    Summary and Conclusions . . . . . 201

11. A SUMMATION . . . . . 202

    Addenda . . . . . 206

INDEX . . . . . 207